COVID-19 in Relation to Chronic Antihistamine Prescription

Overview

Journal Microorganisms

Specialty Microbiology

Date 2025 Jan 8

PMID 39770791

Authors

Anna Puigdellivol-Sanchez

Marta Juanes-Gonzalez

Ana Calderon-Valdiviezo

Helena Losa-Puig

Roger Valls-Foix

Marta Gonzalez-Salvador

Celia Lozano-Paz

Josep Vidal-Alaball

Affiliations

Soon will be listed here.

Abstract

No hospitalizations or deaths occurred in residents with the COVID-19 infection, treated with antihistamines and azithromycin, of two external nursing homes during the first wave. We assessed whether patients receiving chronic antihistamines in our institution showed better clinical evolution. COVID-19 admissions and related deaths in the public Hospital of Terrassa ( = 1461) during the pandemic period (11 March 2020-5 May 2023) and cases ( = 32,888) during the period of full suspicion diagnosis (1 June 2020-23 March 2022) were referred to as the number of chronic treatments (nT) including or not including antihistamines (AntiHm or NOAntiHm), and their vaccination status before the first infection (VAC or NoVAC) in our assigned population ( = 140,681 at March 2020) was recorded. No deaths occurred in patients treated with up to ≤6 nT in the AntiHm group in all ages. A significant reduction in hospital admission was observed in the 2-7 nT groups either below or over 60 years old [Odds Ratio (OR) NoAntiHm/AntiHm = 1.76-1.32, respectively, in NoVAC or VAC (OR = 2.10 overall] and in the older ≥8 nT group (OR = 2.08 in NoVac]. In conclusion, patients with chronic antihistamine prescriptions, alone or with polypharmacy, showed reduced hospital admission and mortality rates, suggesting the safety of antihistamine treatment and the need to confirm its effectiveness in a prospective trial.

References

Saeedi-Boroujeni A, Nashibi R, Ghadiri A, Nakajima M, Salmanzadeh S, Mahmoudian-Sani M . Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial. Arch Med Res. 2022; 53(4):368-377. PMC: 8919799. DOI: 10.1016/j.arcmed.2022.03.002. View

Remuzzi A, Remuzzi G . COVID-19 and Italy: what next?. Lancet. 2020; 395(10231):1225-1228. PMC: 7102589. DOI: 10.1016/S0140-6736(20)30627-9. View

Ghasemi H, Darvishi N, Salari N, Hosseinian-Far A, Akbari H, Mohammadi M . Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies. Trop Med Health. 2022; 50(1):60. PMC: 9427437. DOI: 10.1186/s41182-022-00456-x. View

Reznikov L, Norris M, Vashisht R, Bluhm A, Li D, Liao Y . Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun. 2020; 538:173-179. PMC: 7713548. DOI: 10.1016/j.bbrc.2020.11.095. View

Menzel M, Akbarshahi H, Bjermer L, Uller L . Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep. 2016; 6:28698. PMC: 4923851. DOI: 10.1038/srep28698. View

Fadel R, Morrison A, Vahia A, Smith Z, Chaudhry Z, Bhargava P . Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. 2020; 71(16):2114-2120. PMC: 7314133. DOI: 10.1093/cid/ciaa601. View

Taghioff S, Slavin B, Holton T, Singh D . Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients. PLoS One. 2021; 16(8):e0255541. PMC: 8330918. DOI: 10.1371/journal.pone.0255541. View

Yu F, Liu X, Ou H, Li X, Liu R, Lv X . The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. mBio. 2024; 15(8):e0108824. PMC: 11324024. DOI: 10.1128/mbio.01088-24. View

Tran D, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A . Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019; 72(10):759-768. DOI: 10.1038/s41429-019-0204-x. View

10.

Cortes-Borra A, Aranda-Abreu G . Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. 2021; 73(3):962-965. PMC: 7891470. DOI: 10.1007/s43440-021-00231-5. View

11.

Oh K, Adnan M, Cho D . Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19. Curr Issues Mol Biol. 2022; 44(4):1597-1609. PMC: 9164076. DOI: 10.3390/cimb44040109. View

12.

Savarese G, Benson L, Sundstrom J, Lund L . Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. Eur J Heart Fail. 2020; 23(3):476-485. PMC: 7753665. DOI: 10.1002/ejhf.2060. View

13.

Verdecchia P, Angeli F, Reboldi G . Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. J Hypertens. 2020; 38(6):1190-1191. PMC: 7236844. DOI: 10.1097/HJH.0000000000002469. View

14.

Zubiete-Franco I, Tonks N . Famotidine increases cellular phospho-tyrosine levels. Biochem Biophys Res Commun. 2024; 734:150763. PMC: 11490372. DOI: 10.1016/j.bbrc.2024.150763. View

15.

Puigdellivol-Sanchez A, Juanes-Gonzalez M, Calderon-Valdiviezo A, Valls-Foix R, Gonzalez-Salvador M, Lozano-Paz C . COVID-19 in Relation to Polypharmacy and Immunization (2020-2024). Viruses. 2024; 16(10). PMC: 11512247. DOI: 10.3390/v16101533. View

16.

Atalla E, Zhang R, Shehadeh F, Mylona E, Tsikala-Vafea M, Kalagara S . Clinical Presentation, Course, and Risk Factors Associated with Mortality in a Severe Outbreak of COVID-19 in Rhode Island, USA, April-June 2020. Pathogens. 2020; 10(1). PMC: 7824344. DOI: 10.3390/pathogens10010008. View

17.

Harandi A, Pakdaman H, Medghalchi A, Kimia N, Kazemian A, Siavoshi F . A randomized open-label clinical trial on the effect of Amantadine on post Covid 19 fatigue. Sci Rep. 2024; 14(1):1343. PMC: 10792128. DOI: 10.1038/s41598-024-51904-z. View

18.

Ariza M, Cano N, Segura B, Adan A, Bargallo N, Caldu X . Neuropsychological impairment in post-COVID condition individuals with and without cognitive complaints. Front Aging Neurosci. 2022; 14:1029842. PMC: 9631485. DOI: 10.3389/fnagi.2022.1029842. View

19.

Dinnes J, Deeks J, Berhane S, Taylor M, Adriano A, Davenport C . Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021; 3:CD013705. PMC: 8078597. DOI: 10.1002/14651858.CD013705.pub2. View

20.

Zhong G, Li J, Wang H . Identification of HRH1 as an alternative receptor for SARS-CoV-2: insights from viral inhibition by repurposable antihistamines. mBio. 2024; 15(8):e0169724. PMC: 11323543. DOI: 10.1128/mbio.01697-24. View